SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion, primarily driven by the ongoing, contentious acquisition saga surrounding Warner Bros. Discovery, which continues to generate significant uncertainty. This prolonged situation, compounded by mixed analyst sentiment, has led to sharply divided investor opinions, with many debating the stock's "oversold" status as it navigates a challenging environment ahead of its earnings report.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point as the bank kicks off earnings season, with community discussions intensely focused on recent warnings about rising expenses and the potential impact of a proposed credit card interest rate cap. Investors are also digesting the bank's strategic move to take over the Apple Card program and its deeper foray into blockchain and tokenized funds, all while online chatter includes speculation regarding its market positions in commodities.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is gaining attention following a new pre-production order for GPU-accelerated systems for U.S. Army combat vehicles, which is amplifying community anticipation for a much larger defense contract in the burgeoning Edge AI sector. Investors are bullish on the company's focused strategy after a recent asset sale, coupled with its specialized technology, low stock float, and potential for significant growth in defense and AI infrastructure. Discussions highlight the company's strong positioning for future defense spending and AI compute needs at the tactical level.

KOLANA is a koala-character meme coin that has been designed as the newest meme character token to join the Solana ecosystem. It’s a fun, community-driven token with no inherent value, created purely for those who want to participate in the Solana meme culture and become a part of the KOLANA community. While it doesn't offer utility or financial promises, it thrives on community engagement and decentralised fun.

KOLANA

KOLANA CRYPTO is trending as it captures increasing market interest, with community members highlighting its early signs of strength and ability to hold structure amidst volatility. Enthusiasts are actively discussing its steady momentum and balanced movement, advocating for early participation in this crypto asset.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics (TVTX) is generating intense market conversation and significant volatility due to a recent FDA request for additional data to further characterize FILSPARI's clinical benefit for its potential FSGS indication, despite the company reiterating confidence and reporting robust sales for its existing IgAN approval. This immediate uncertainty has polarized the community, with many speculating on a Complete Response Letter (CRL) while others perceive the sharp sell-off as an overreaction, viewing it as a buying opportunity given the high unmet medical need in FSGS.

Lulu's Fashion Lounge Holdings, Inc. engages in providing an online website for clothing. It offers retailing of women's clothing, shoes, and accessories. The company was founded in 1996 and is headquartered in Chico, CA.

Lulus Fashion Lounge Holdings Inc

Lulus Fashion Lounge (LVLU) is trending due to activist investor Christian Friedland's disclosed stake and call for significant governance reforms, emphasizing the company's "extremely undervalued" status. The community is actively discussing Friedland's assertion that LVLU trades at a 27x valuation gap compared to peers, despite achieving positive adjusted EBITDA and expanded gross margins. This has ignited speculation among traders about a potential "super squeeze" and multi-day run, driven by the proposed reforms and perceived undervaluation.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix is experiencing significant upward momentum following preliminary Q4 and full-year 2025 results that exceeded guidance, showing strong revenue growth. This positive update, coupled with its small float, is fueling intense discussion among traders actively debating its breakout potential and the possibility of a short squeeze, despite ongoing concerns about future dilution.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as new iGaming legalizations, notably in Maine, and ongoing discussions in other states like New York and Virginia, signal expansion opportunities. The community is actively debating the impact of its recently launched prediction markets platform, while many anticipate strong engagement and revenue from the upcoming NFL playoffs and Super Bowl. This growth is viewed against persistent frustrations over the stock's current valuation despite underlying business momentum and ongoing efforts to expand its regulated online betting footprint.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is experiencing notable volatility and intense community debate after announcing a CFO transition and reiterating its strategy to prioritize long-term user growth and product investment. While some investors view the significant stock decline as an attractive buying opportunity, others express deep concerns about its valuation and the ongoing discussion surrounding AI's potential to disrupt its core business model. The broader conversation centers on Duolingo's capacity to sustain its competitive moat within the dynamic education technology sector.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi (FRMI) is heavily trending after a significant stock decline triggered by the termination of a $150 million funding agreement with a prospective tenant for its Project Matador AI data center campus, coupled with news of a class-action lawsuit. Community sentiment is sharply divided: while many criticize its lack of revenue and call it an "IPO fraud," bullish investors view the sell-off as an overreaction, emphasizing its strategic role in providing critical power for AI data centers and anticipating future lucrative tenant agreements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MannKind (NASDAQ:MNKD) Insider Stuart Tross Sells 47,006 Shares

MannKind Corporation (NASDAQ:MNKD - Get Free Report) insider Stuart Tross sold 47,006 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an...

<ul class="summary-bullets"><li>MannKind is now eyeing a potential approval of its Afrezza inhalation powder for children and adolescents living with type 1 or type 2 diabetes.</li><li>H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update.</li><li>The firm said it is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026."</li></ul>MannKind Corporation (MNKD) on Thursday said that it expects two high potential launches going into 2026, driving investor optimism and sending shares up 2%.&nbsp; “With two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation,” CEO Michael Castagna<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/08/3215359/29517/en/MannKind-Provides-Business-Updates-and-2026-Growth-Drivers.html"> said,</a> while adding that the company closed 2025 “on a high note” with its acquisition of scPharmaceuticals.<h2 class="st-heading-2">MannKind’s Potential Launches</h2>MannKind is now eyeing a potential approval of its Afrezza inhalation powder for children and adolescents living with type 1 or type 2 diabetes. The U.S. Food and Drug Administration is expected to rule on the application by May 29 and if approved, it would be the first needle-free insulin option for pediatric patients in over 100 years of insulin therapy, the company said.The company is also eyeing approval for its FUROSCIX ReadyFlow Autoinjector, developed to deliver a subcutaneous furosemide injection in under 10 seconds as an investigational alternative to the FDA-approved FUROSCIX On-body Infusor. Furosemide is used for treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD).<h2 class="st-heading-2">Analyst Weighs In</h2>H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update. The price target represents a potential upside of about 88% from the stock's closing price on Wednesday.&nbsp;The firm said it is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MNKD shares jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user dismissed the company’s Thursday update as “another pump and dump.”<stembedurl>https://www.stocktwits.com/Kool_Aid_Mann/message/641251643</stembedurl><a href="https://stocktwits.com/symbol/MNKD">MNKD stock</a> has dropped 3% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-stock-rallies-on-piper-sandler-upgrade-plans-to-launch-autonomous-driving-on-30000-ev/cmUbiTNR45X">Ford Stock Rallies On Piper Sandler Upgrade, Plans To Launch Autonomous Driving On $30,000 EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026

The company’s CEO Michael Castagna said that with two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation. 

Equity

MannKind (NASDAQ:MNKD) Reaches New 52-Week High - What's Next?

MannKind (NASDAQ:MNKD) Hits New 12-Month High - Here's Why...

Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD

Voya Investment Management LLC cut its holdings in MannKind Corporation (NASDAQ:MNKD - Free Report) by 89.7% in the third quarter, according to its most recent Form 13F filing with the Securities and...

Calamos Advisors LLC Acquires New Position in MannKind Corporation $MNKD

Calamos Advisors LLC acquired a new stake in shares of MannKind Corporation (NASDAQ:MNKD - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange...

180 Wealth Advisors LLC Increases Stock Position in MannKind Corporation $MNKD

180 Wealth Advisors LLC lifted its position in shares of MannKind Corporation (NASDAQ:MNKD - Free Report) by 11.2% during the third quarter, according to the company in its most recent filing with...

MannKind (NASDAQ:MNKD) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

MannKind (NASDAQ:MNKD) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened...

Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?

Key PointsCEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per share...

<ul class="summary-bullets"><li>The FDA expanded Furoscix use to certain pediatric patients.</li><li>MannKind received five new U.S. patents supporting its ReadyFlow autoinjector, which is still under FDA review.</li><li>The FDA is expected to decide on the ReadyFlow application by July 26, 2026.</li></ul>MannKind Corp (MNKD) shares fell on Tuesday even as the company announced regulatory and patent updates tied to its&nbsp;Furoscix drug, which is used to treat fluid buildup in people with heart failure and kidney disease.At the time of writing, the stock fell 1.4% to $5.91.<h2 class="st-heading-2">Furoscix Gets Pediatric Approval</h2>The company said the U.S. Food and Drug Administration (FDA) approved wider use of&nbsp;Furoscix to include certain pediatric patients who weigh at least 43 kilograms. The drug was previously approved only for adults with fluid buildup caused by chronic heart failure or chronic kidney disease.The company’s chief medical officer said the approval makes&nbsp;Furoscix available to a limited pediatric group and provides an option for treatment outside the hospital for patients who meet the weight requirement.<h2 class="st-heading-2">Patents Support ReadyFlow Autoinjector</h2>MannKind also said it received five new U.S. patents related to its ReadyFlow autoinjector, a device under FDA review that is designed to deliver furosemide in seconds rather than hours.The patents cover the drug formulation and methods of treatment and could provide protection through 2040 if the product is approved. The company said the patents would be listed in the FDA’s Orange Book upon approval.ReadyFlow is based on technology developed by scPharmaceuticals, which MannKind acquired in August. Before the acquisition, scPharmaceuticals reported positive study results showing that the autoinjector delivered furosemide at levels comparable to intravenous dosing. In that study, patients had similar fluid removal results to IV treatment, reported little to no injection pain, and experienced side effects consistent with standard furosemide use.The company reiterated that the FDA is reviewing its application for ReadyFlow for use in adults with heart failure or kidney disease, with a decision expected by July 26, 2026.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for MannKind was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:970/141;" src="https://news.stocktwits-cdn.com/mnkd_ss_png_2d06a45896.webp" alt="mnkd ss.png" width="970" height="141"><figcaption>MNKD sentiment and message volume as of December 23| Source: Stocktwits</figcaption></figure>One user said the pediatric approval carries limited commercial impact but signals regulatory comfort with&nbsp;Furoscix, which could be supportive ahead of the FDA’s July 2026 decision on the ReadyFlow autoinjector.<stembedurl>https://stocktwits.com/kevinmik/message/639971814</stembedurl>Another retail investor questioned the timing of the announcement, noting it was released just ahead of the Christmas holiday when market activity is typically thin.<stembedurl>https://stocktwits.com/ChillyMutt/message/639959660</stembedurl><a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined 0.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MannKind’s stock has declined 0.9% so far in 2025. (Photo credit: Getty Images)

MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors?

Shares fell as investors flagged limited commercial impact from the pediatric approval and questioned the timing of the announcement during thin holiday trading.

Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock

MannKind Corporation (NASDAQ:MNKD - Get Free Report) CEO Michael Castagna sold 65,804 shares of the business's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold...

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

MNKD
Mannkind Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MNKD News

MNKDMannkind Corp